Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation Academic Article uri icon

Overview

MeSH Major

  • Breast Neoplasms
  • Gene Expression Profiling
  • Mammary Neoplasms, Experimental

abstract

  • Ipilimumab is a first-in-class immunological checkpoint blockade agent and monoclonal antibody against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) that has demonstrated survival benefit and durable responses in patients with metastatic melanoma. To date, solid organ transplant recipients have been excluded from clinical trials with cancer immunotherapies on the basis of their concurrent treatment with immunosuppressive agents. We present the first case to our knowledge of a patient with advanced cutaneous melanoma receiving ipilimumab status post orthotopic liver transplantation with a partial response. Transaminitis was observed 4¬†months after administration of ipilimumab that resolved with close observation. No evidence of graft rejection has been observed to date. This case advocates for further investigation of the safety and efficacy of cancer immunotherapies in solid organ transplant recipients.

publication date

  • June 16, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4469313

Digital Object Identifier (DOI)

  • 10.1186/s40425-015-0066-0

PubMed ID

  • 26082835

Additional Document Info

start page

  • 22

volume

  • 3

number

  • 1